Michelle Ang Camerino

This inventor holds 16 USPTO granted patents and 10 published patent applications, plus 1 CIPO patent and 13 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Ctxt Pty Limited, Cancer Therapeutics Crc Pty Limited, Pfizer Corporation. Active years: 2016-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michelle Ang Camerino. Retrieved from https://idiyas.com/inventor/michelle-ang-camerino

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 16 (Patent Applications = 10)

% Patents Active = 87.5

CIPO Patents = 1 (Patent Applications = 6)

EPO Patents = 13 (Patent Applications = 16)

Average Co-Inventor Count = 5.7

ph-index = 3

Forward Citations = 21(Granted Patents)

Location History:

Victoria, AU (2018 - 2021)
Parkville, AU (2016 - 2024)

Company Filing History:

Cancer Therapeutics Crc Pty Limited

where one patent can have more than one assignee

Years Active: 2016-2025

Loading Chart...

Areas of Expertise:

STING Modulators

PRMT5 Inhibitors

Benzothiophene Derivatives

Thienopyridine Derivatives

Benzisoxazole Derivatives

Tetrahydroisoquinolines

Cancer Treatment

Hemoglobinopathies

VEGFR3 Inhibitors

Aminoindane Derivatives

Asparagine Methyl Transferase Inhibitors

Thiophenes

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12415785 - Compound modulators of sting (2025-09-16),

2. 12384801 - Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting (2025-08-12),

3. 12371425 - Benzisoxazole sulfonamide derivatives (2025-07-29),

4. 12365655 - Compounds (2025-07-22),

5. 11911372 - Compounds (2024-02-27),

6. 11613525 - Substituted condensed thiophenes as modulators of sting (2023-03-28),

7. 11492346 - Benzisoxazole sulfonamide derivatives (2022-11-08),

8. 10961256 - PRMT5 inhibitors (2021-03-30),

9. 10787434 - Benzopiperdine derivatives and their use in the treatment of cancer and hemoglobinopathies (2020-09-29),

10. 10647708 - Tetrahydroisoquinoline derived PRMT5-inhibitors (2020-05-12),

11. 10494376 - Tetrahydroisoquinoline derived PRMT5-inhibitors (2019-12-03),

12. 10421743 - Tetrahydroisoquinolines as PRMT5 inhibitors (2019-09-24),

13. 10005792 - Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors (2018-06-26),

14. 9856252 - 2-(hetero)aryl-benzimidazole and imidazopyridine derivatives as inhibitors of asparagime emethyl transferase (2018-01-02),

15. 9266864 - VEGFR3 inhibitors (2016-02-23),

Title: Biography of Michelle Ang Camerino

Introduction: Michelle Ang Camerino is an accomplished inventor based in Victoria, Australia. She has made significant contributions to the field of pharmaceutical sciences, particularly in the modulation of STING (Stimulator of Interferon Genes). With a total of 16 patents to her name, her work has the potential to impact the treatment and prevention of various diseases.

Latest Patents: Among her latest patents is a disclosure related to compounds of formula (I), which are modulators of STING. This patent outlines pharmaceutical compositions that comprise these compounds and methods for their use in treating or preventing diseases that can be ameliorated by the modulation of STING. Another notable patent involves benzothiophene, thienopyridine, and thienopyrimidine derivatives for the modulation of STING, detailing a compound of formula (I) where specific variables are defined to enhance its efficacy.

Career Highlights: Throughout her career, Michelle has worked with various organizations, including Ctxt Pty Limited and Cancer Therapeutics CRC Pty Limited. Her expertise in pharmaceutical development has positioned her as a key player in her field.

Collaborations: Michelle has collaborated with notable professionals such as Paul Anthony Stupple and Scott Raymond Walker. These partnerships have further enriched her research and innovation efforts.

Conclusion: Michelle Ang Camerino's contributions to the field of pharmaceutical sciences through

Profile summary based on public USPTO records.